




Semaglutide

Revised: September 15, 2023.

CASRN: 910463-68-2



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of semaglutide during breastfeeding. Because semaglutide is a peptide molecule with a molecular weight of 4113 Da and is over 99% protein bound, the amount in milk is likely to be very low. Furthermore, semaglutide is only 0.4% to 1% orally absorbed, so it is unlikely to adversely affect the breastfed infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acarbose, Glipizide, Glyburide, Insulin, Metformin, Miglitol

Substance Identification

Substance Name

Semaglutide

CAS Registry Number

910463-68-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Hypoglycemic Agents

Incretins

Glucagon-Like Peptide-1 Agonists

GLP-1 Agonists